Subject enrollment for a phase II study has already begun
This is a multicenter, randomized, double-blind, placebo-controlled study in patients with obliterating atherosclerosis of the lower limb vessels.
The study aim is to evaluate the efficacy and safety of a drug. The participants of the study will include male and female patients, ages 40-70. The duration of the treatment period will be up to 10 days. In total, the study assumes an enrollment of more than 300 patients.
The OCT team is responsible for site selection, monitoring, project management, logistics, medical writing, and data management.Back to the list